Transglutaminase 3 as a prognostic biomarker in esophageal cancer revealed by proteomics

International Journal of Cancer

Volumn 124, Issue 9, 2009, Pages 2106-2115

  Uemura, Norihisa ^a,b,c   Nakanishi, Yukihiro ^a   Kato, Hoichi ^b   Saito, Shigeru ^a,d   Nagino, Masato ^c   Hirohashi, Setsuo ^a   Kondo, Tadashi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Infocom Corporation   (Japan)

Author keywords

Esophageal cancer; Prognosis; Proteomics; TGM3 protein; Two dimensional difference gel electrophoresis

Indexed keywords

PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 3; UNCLASSIFIED DRUG; TGM3 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; AGED; CANCER INVASION; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; DISEASE COURSE; ECHOCARDIOGRAPHY; ENZYME IMMUNOASSAY; ENZYMOLOGY; ESOPHAGUS TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TISSUE MICROARRAY; TUMOR RECURRENCE;

AGED; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TRANSGLUTAMINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 63449097614     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24194     Document Type: Article

References (46)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827-841
2. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29.
3. Ilson DH. Oesophageal cancer: new developments in systemic therapy. Cancer Treat Rev 2003;29:525-532 (Pubitemid 37428324)
4. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241-2252 (Pubitemid 37485141)
5. Mariette C, Balon JM, Piessen G, Fabre S, Van Seuningen I, Triboulet JP. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer 2003;97:1616-1623 (Pubitemid 36350704)
6. Shinoda M, Hatooka S, Mori S, Mitsudomi T. Clinical aspects of multimodality therapy for resectable locoregional esophageal cancer. Ann Thorac Cardiovasc Surg 2006;12:234-241
7. Ando N, Iizuka T, Kakegawa T, Isono K, Watanabe H, Ide H, Tanaka O, Shinoda M, Takiyama W, Arimori M, Ishida K, Tsugane S. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg 1997;114:205-209 (Pubitemid 27364210)
8. Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, Takiyama W, Watanabe H, Isono K, Aoyama N, Makuuchi H, Tanaka O, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study-JCOG9204. J Clin Oncol 2003;21:4592-4596
9. Tamoto E, Tada M, Murakawa K, Takada M, Shindo G, Teramoto K, Matsunaga A, Komuro K, Kanai M, Kawakami A, Fujiwara Y, Kobayashi N, et al. Gene-expression profile changes correlated with tumor progression and lymph node metastasis in esophageal cancer. Clin Cancer Res 2004;10:3629-3638
10. Kan T, Shimada Y, Sato F, Ito T, Kondo K, Watanabe G, Maeda M, Yamasaki S, Meltzer SJ, Imamura M. Prediction of lymph node metastasis with use of artificial neural networks based on gene expression profiles in esophageal squamous cell carcinoma. Ann Surg Oncol 2004;11:1070-1078 (Pubitemid 40486653)
11. Gomes LI, Esteves GH, Carvalho AF, Cristo EB, Hirata R, Jr, Martins WK, Marques SM, Camargo LP, Brentani H, Pelosof A, Zitron C, Sallum RA, et al. Expression profile of malignant and nonmalignant lesions of esophagus and stomach: differential activity of functional modules related to inflammation and lipid metabolism. Cancer Res 2005;65:7127-7136
12. Vallbohmer D, Lenz HJ. Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis Esophagus 2006;19:425-432 (Pubitemid 44644677)
13. Chen G, Gharib TG, Huang CC, Taylor JM, Misek DE, Kardia SL, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM, Beer DG. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 2002;1:304-313
14. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, Wei JT, Pienta KJ, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005;8:393-406.
15. Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein andmRNA abundance in yeast. Mol Cell Biol 1999;19:1720-1730 (Pubitemid 29098230)
16. Sobin L, Wittekind C. UICC TNM Classification of malignant tumors, 6th edn. New York: Wiley-Liss, 2002.
17. Kondo T, Seike M, Mori Y, Fujii K, Yamada T, Hirohashi S. Application of sensitive fluorescent dyes in linkage of laser microdissection and two-dimensional gel electrophoresis as a cancer proteomic study tool. Proteomics 2003;3:1758-1766 (Pubitemid 37129823)
18. Kondo T, Hirohashi S. Application of highly sensitive fluorescent dyes (CyDye DIGE Fluor saturation dyes) to laser microdissection and two-dimensional difference gel electrophoresis (2D-DIGE) for cancer proteomics. Nat Protoc 2006;1:2940-2956
19. Cheadle C, Vawter MP, Freed WJ, Becker KG. Analysis of microarray data using Z score transformation. J Mol Diagn 2003;5:73-81. (Pubitemid 36553428)
20. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289-300.
21. Okano T, Kondo T, Kakisaka T, Fujii K, Yamada M, Kato H, Nishimura T, Gemma A, Kudoh S, Hirohashi S. Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis. Proteomics 2006;6:3938-3948 (Pubitemid 44065171)
22. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
23. Tachibana M, Kinugasa S, Yoshimura H, Shibakita M, Tonomoto Y, Dhar DK, Nagasue N. Clinical outcomes of extended esophagectomy with three-field lymph node dissection for esophageal squamous cell carcinoma. Am J Surg 2005;189:98-109. (Pubitemid 40215515)
24. Lee JH, Jang SI, Yang JM, Markova NG, Steinert PM. The proximal promoter of the human transglutaminase 3 gene. Stratified squamous epithelial-specific expression in cultured cells is mediated by binding of. Sp1 and ets transcription factors to a proximal promoter element. J Biol Chem 1996;271:4561-4568
25. Aloia TA, Harpole DH, Jr, Reed CE, Allegra C, Moore MB, Herndon JE, II, D'Amico TA. Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann Thorac Surg 2001;72:859-866 (Pubitemid 32846247)
26. Hitomi K, Presland RB, Nakayama T, Fleckman P, Dale BA, Maki M. Analysis of epidermal-type transglutaminase (transglutaminase 3) in human stratified epithelia and cultured keratinocytes using monoclonal antibodies. J Dermatol Sci 2003;32:95-103. (Pubitemid 36870755)
27. Liu W, Yu ZC, Cao WF, Ding F, Liu ZH. Functional studies of a novel oncogene TGM3 in human esophageal squamous cell carcinoma. World J Gastroenterol 2006;12:3929-3932 (Pubitemid 44028412)
28. Ishikura S, Nihei K, Ohtsu A, Boku N, Hironaka S, Mera K, Muto M, Ogino T, Yoshida S. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 2003;21:2697-2702 (Pubitemid 46606313)
29. Igaki H, Kato H, Tachimori Y, Sato H, Daiko H, Nakanishi Y. Prognostic evaluation for squamous cell carcinomas of the lower thoracic esophagus treated with three-field lymph node dissection. Eur J Cardiothorac Surg 2001;19:887-893 (Pubitemid 32515246)
30. Hirasaki S, Noguchi T, Mimori K, Onuki J, Morita K, Inoue H, Sugihara K, Mori M, Hirano T. BAC clones related to prognosis in patients with esophageal squamous carcinoma: an array comparative genomic hybridization study. Oncologist 2007;12:406-417 (Pubitemid 46698718)
31. Uchikado Y, Inoue H, Haraguchi N, Mimori K, Natsugoe S, Okumura H, Aikou T, Mori M. Gene expression profiling of lymph node metastasis by oligomicroarray analysis using laser microdissection in esophageal squamous cell carcinoma. Int J Oncol 2006;29:1337-1347
32. Watanabe G, Kaganoi J, Imamura M, Shimada Y, Itami A, Uchida S, Sato F, Kitagawa M. Progression of esophageal carcinoma by loss of EGF-STAT1 pathway. Cancer J 2001;7:132-139 (Pubitemid 32303550)
33. Shimaya K, Shiozaki H, Inoue M, Tahara H, Monden T, Shimano T, Mori T. Significance of p53 expression as a prognostic factor in oesophageal squamous cell carcinoma. Virchows Arch A Pathol Anat Histopathol 1993;422:271-276 (Pubitemid 23169371)
34. Sarbia M, Porschen R, Borchard F, Horstmann O, Willers R, Gabbert HE. p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 1994;74:2218-2223 (Pubitemid 2148227)
35. Furihata M, Ohtsuki Y, Ogoshi S, Takahashi A, Tamiya T, Ogata T. Prognostic significance of human papillomavirus genomes (type-16, - 18) and aberrant expression of p53 protein in human esophageal cancer. Int J Cancer 1993;54:226-230 (Pubitemid 23154886)
36. Wang DY, Xiang YY, Tanaka M, Li XR, Li JL, Shen Q, Sugimura H, Kino I. High prevalence of p53 protein overexpression in patients with esophageal cancer in Linxian. China and its relationship to progression and prognosis. Cancer 1994;74:3089-3096
37. Piessen G, Jonckheere N, Vincent A, Hemon B, Ducourouble MP, Copin MC, Mariette C, Van Seuningen I. Regulation of the human mucin MUC4 by taurodeoxycholic and taurochenodeoxycholic bile acids in oesophageal cancer cells is mediated by hepatocyte nuclear factor 1alpha. Biochem J 2007;402:81-91. (Pubitemid 46254910)
38. Carraway KL, Ramsauer VP, Haq B, Carothers Carraway CA. Cell signaling through membrane mucins. Bioessays 2003;25:66-71. (Pubitemid 36093327)
39. Singh AP, Moniaux N, Chauhan SC, Meza JL, Batra SK. Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res 2004;64:622-630 (Pubitemid 38120902)
40. Fauquette V, Perrais M, Cerulis S, Jonckheere N, Ducourouble MP, Aubert JP, Pigny P, Van Seuningen I. The antagonistic regulation of human MUC4 and ErbB-2 genes by the Ets protein PEA3 in pancreatic cancer cells: implications for the proliferation/differentiation balance in the cells. Biochem J 2005;386:35-45. (Pubitemid 40289222)
41. Mendez E, Fan W, Choi P, Agoff SN, Whipple M, Farwell DG, Futran ND, Weymuller EA, Jr, Zhao LP, Chen C. Tumor-specific genetic expression profile of metastatic oral squamous cell carcinoma. Head Neck 2007;29:803-814 (Pubitemid 350303667)
42. Pennathur A, Luketich JD. Resection for esophageal cancer: strategies for optimal management. Ann Thorac Surg 2008;85:S751-6.
43. Kalinin AE, Kajava AV, Steinert PM. Epithelial barrier function: assembly and structural features of the cornified cell envelope. Bioessays 2002;24:789-800.
44. Kim IG, Gorman JJ, Park SC, Chung SI, Steinert PM. The deduced sequence of the novel protransglutaminase E (TGase3) of human and mouse. J Biol Chem 1993;268:12682-12690 (Pubitemid 23182433)
45. Chen BS, Wang MR, Xu X, Cai Y, Xu ZX, Han YL, Wu M. Transglutaminase- 3, an esophageal cancer-related gene. Int J Cancer 2000;88:862-865
46. Luo A, Kong J, Hu G, Liew CC, Xiong M, Wang X, Ji J, Wang T, Zhi H, Wu M, Liu Z. Discovery of Ca21-relevant and differentiation-associated genes downregulated in esophageal squamous cell carcinoma using cDNA microarray. Oncogene 2004;23:1291-1299 (Pubitemid 38297184)